XenoGenis doubles Nottingham footprint in BioCity expansion

posted by Phill Allen

October, 12th, 2018

Company News Pharmaceutical Industry News

The UK’s largest independent laboratory-based contract research organisation, XenoGenis, has announced the opening of its new labs in the Nottingham based BioCity Discovery Building.
XenoGenis doubles Nottingham footfall in BioCity expansion
The move, which has been made possible by the Government’s Regional Growth fund, as well as the University of Derby Invest to Grow Programme, has allowed the company to take on the 5,500ft space, effectively doubling its footprint within the city. This follows an initial move into the labs which happened over the summer.
XenoGenis currently employs 26 staff with plans for “significant” growth in the future. In what marks an exciting time for the company and Nottingham itself, XenoGenis founder and current Managing Director Richard Weaver told The Business Desk: “It was fantastic to celebrate the official opening of our new labs and offices at the Discovery Building, which will provide us with the space we need to embark on our next phase of growth.”
He added: “We are thrilled with our new bespoke facilities which will provide an enhanced working environment for our growing team as well as accommodating our plans to expand our service offering for our clients, who we look forward to welcoming to XenoGesis.”
The opening of the new facilities was held amongst the backdrop of a grand reception, in which 60 guests attended on September 24.

TAGS: biotechnology, Nottingham, Pharmaceutical, XenoGenis,

SHARE:

Avatar photo

Author

Phill Allen

Managing Director

An in and outside the (bioprocess) box thinker, fluid management specialist Phill knows a thing or two about keeping pharma liquid logistics flowing.

ALLpaQ and the Importance of our ISO 9001 Renewal
Company News

ALLpaQ and the Importance of our ISO 9001 Renewal

ALLpaQ is proud to confirm that we have successfully renewed our ISO 9001:2015 certification (Cert. 23250). This milestone wouldn’t have […]

Jan 26th, 2024